EUCTR2007-003956-12-IT进行中（未招募）不适用
Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial - ND
OVO NORDISK0 个研究点目标入组 517 人开始时间: 2008年7月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 517
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)
- •2.Men and women-not-of-childbearing-potential diagnosed with type 2 diabetes for at least three months prior to trial
- •3.Men and women-not-of-childbearing-potential treated with diet and exercise alone, or who have been on stable doses of metformin (≥ 1500 mg) for at least three months prior to trial
- •The definition of women-not-of-childbearing-potential is: females who have been permanently sterilised (i.e. hysterectomy or bilateral oophorectomy), or who are postmenopausal (i.e. at least 6 months of spontaneous amenorrhoea with serum follicle stimulating hormone (FSH) >40 mU/mL.)
- •4.HbA1c: 7.0-10.0% (both inclusive)
- •5.Age 18 years, (as allowed according to local guidelines for metformin)
- •6.Body weight: 60.0 kg < body weight < 110.0 kg
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Treatment with insulin, GLP-1 receptor agonists (including liraglutide), DPP-4 inhibitors, sulphonylurea, thiazolidinediones or Alpha-GIs within the last three months prior to the trial (except for short-term treatment with insulin in connection with an intercurrent illness at the discretion of the Investigator)
- •2.Impaired liver function, defined as alanine aminotransferase (ALAT) 2.5 times upper limit of normal (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being conclusive)
- •3.Subjects known to be Hepatitis B antigen or Hepatitis C antibody positive
- •4.Impaired renal function defined as serum-creatinine 135 mol/L ( 1.53 mg/dL) for males and 120 mol/L ( 1.23 mg/dL) for females (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being conclusive)
- •5.Proliferative retinopathy or maculopathy requiring acute treatment as judged by the Investigator
- •6.Clinically significant active cardiovascular disease including history of myocardial infarction within the past six months and/or heart failure (New York Heart Association (NYHA) class III and IV ) at the discretion of the Investigator.
- •7.Uncontrolled treated/untreated hypertension (systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg)
- •8.Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer)
- •9.Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator.
- •10.Known or suspected allergy to trial product(s) or related products
- •11.Present or planned use of any drug (except for metformin), which in the Investigator?s opinion could interfere with the glucose levels (e.g. systemic cortisteroids)
- •12.The receipt of any investigational drug within three months prior to screening into this trial
- •13.Previous participation in the randomised phase of this trial. Re-screening is allowed once within the limits of the recruitment period.
- •14.Known or suspected abuse of alcohol or narcotics
- •15.Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
研究者
相似试验
进行中（未招募）
不适用
Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trialtype 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003956-12-HUovo Nordisk A/S517
进行中（未招募）
不适用
Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trialtype 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003956-12-FIovo Nordisk A/S517
进行中（未招募）
1 期
Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exercise A 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trialtype 2 diabetes mellitusMedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusEUCTR2007-003956-12-GBovo Nordisk A/S517
进行中（未招募）
不适用
Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trialtype 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003956-12-DEovo Nordisk A/S517
进行中（未招募）
1 期
Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trialEUCTR2007-003956-12-FRovo Nordisk A/S517